Compare FNWB & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNWB | NRXS |
|---|---|---|
| Founded | 1923 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1M | 78.9M |
| IPO Year | 2012 | 2023 |
| Metric | FNWB | NRXS |
|---|---|---|
| Price | $10.61 | $6.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.50 | $13.00 |
| AVG Volume (30 Days) | 28.1K | ★ 129.5K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | $176,000.00 | ★ $3,569,282.00 |
| Revenue This Year | $19.24 | $172.91 |
| Revenue Next Year | $8.90 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $7.05 | $2.20 |
| 52 Week High | $10.98 | $9.33 |
| Indicator | FNWB | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.44 | 42.02 |
| Support Level | $10.39 | $6.24 |
| Resistance Level | $10.98 | $7.79 |
| Average True Range (ATR) | 0.27 | 0.44 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 84.11 | 33.59 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).